XML 29 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Other Intangible Assets

12 Months Ended

Dec. 31, 2023

Intangible Assets Disclosure [Text Block]

NOTE 8. OTHER INTANGIBLE ASSETS

As of December 31, 2023 and 2022, other intangible assets consisted of the following (in thousands):

	Balance at December 31, 2023
			Accumulated			Impairments
	Gross		Amortization			to Date			Net
Indefinite-lived intangible assets
Trade names	$	2,080	$	—		$	(2,080	)	$	—

Amortizable intangible assets
Customer relationships		290		(60	)		(230	)		—
Trade secrets / product formulations		2,890		(515	)		(2,375	)		—

Total other intangible assets	$	5,260	$	(575	)	$	(4,685	)	$	—

	Balance at December 31, 2022
			Accumulated			Impairments
	Gross		Amortization			to Date			Net
Indefinite-lived intangible assets
Trade names	$	2,080	$	—		$	(970	)	$	1,110

Amortizable intangible assets
Customer relationships		290		(48	)		(172	)		70
Trade secrets / product formulations		2,890		(375	)		(1,415	)		1,100

Total other intangible assets	$	5,260	$	(423	)	$	(2,557	)	$	2,280

In each of the fourth quarters of 2023 and 2022, the Company determined that certain of its indefinite-lived and long-lived amortizable intangible assets related to its DERMAdoctor business were impaired, including fully impaired as of December 31, 2023. As such, the Company recorded an intangible asset impairment charge of $2.1 million and $2.6 million in the years ended December 31, 2023 and 2022, respectively, which is reflected in the goodwill, intangible and other asset impairment caption in the Company’s consolidated statements of operations. The impairment information is discussed in Note 2, “Summary of Significant Accounting Policies”. Subsequent to December 31, 2023, on March 25, 2024, we closed the DERMAdoctor Divestiture. See additional information in Note 21, “Subsequent Events”.

Amortization expense was $152 thousand and $363 thousand for the years ended December 31, 2023 and 2022, respectively.